UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Synthesis of Blue-Luminescent Seven-Membered Phosphorus Heterocycles

Journal of organic chemistry, 2020-01, Vol.85 (2), p.1247-1252

2020

Volltextzugriff (PDF)

Calix[4]pyrrolato Stannate(II): A Tetraamido Tin(II) Dianion and Strong Metal‐Centered σ‐Donor

Angewandte Chemie International Edition, 2022-03, Vol.61 (13), p.e202116615-n/a

2022

Volltextzugriff (PDF)

Calix4pyrrolato Stannate(II): A Tetraamido Tin(II) Dianion and Strong Metal-Centered σ-Donor

Angewandte Chemie International Edition, 2022-03, Vol.61 (13), p.e202116615

2022

Volltextzugriff (PDF)

Calixpyrrolato Stannate(II): A Tetraamido Tin(II) Dianion and Strong Metal‐Centered σ‐Donor

Angewandte Chemie International Edition, 2022-03, Vol.61 (13)

International ed. in English, 2022

Volltextzugriff (PDF)

Bis(alizarinato)silane: In Silico Design and Synthesis of a Powerful Chromogenic Lewis Acid as a Dual-Gated Fluoride Ion Probe

Organometallics, 2020-12, Vol.39 (23), p.4340-4349

2020

Volltextzugriff (PDF)

Calix[4]pyrroles as ligands: recent progress with a focus on the emerging p-block element chemistry

Chemical communications (Cambridge, England), 2021-11, Vol.57 (89), p.11751-11763

2021

Volltextzugriff (PDF)

Conformational and Substitution Effects on the Donor and Reducing Strength of Tin(II) Porphyrinogens

Chemistry : a European journal, 2024-08, Vol.30 (43), p.e202401685-n/a

2024

Volltextzugriff (PDF)

Calix[4]pyrrolatostannat(II): Ein Tetraamidozinn(II)dianion als starker, metallzentrierter σ‐Donor

Angewandte Chemie, 2022-03, Vol.134 (13), p.n/a

2022

Volltextzugriff (PDF)

Calixpyrrolatostannat(II): Ein Tetraamidozinn(II)dianion als starker, metallzentrierter σ‐Donor

Angewandte Chemie, 2022-03, Vol.134 (13)

2022

Volltextzugriff (PDF)

Concatenating Structural Constraint Effects at Tin for the Sequential Generation, Stabilization, and Transfer of Acyclic Aminocarbenes

Journal of the American Chemical Society, 2024-04, Vol.146 (16), p.11515-11522

2024

Volltextzugriff (PDF)

Dynamic Coordination Behavior of a Structurally Constrained, Nucleophilic Sn(II) Towards Gold(I)

Zeitschrift für anorganische und allgemeine Chemie (1950), 2024-08, Vol.650 (16), p.n/a

2024

Volltextzugriff (PDF)

Erprobt, abgestimmt und als (S-)klasse befunden

Sonderprojekte ATZ/MTZ, 2020-12, Vol.25 (Suppl 1), p.150-157

2020

Volltextzugriff (PDF)

Komfort und Sportlichkeit

ATZextra, 2013-07, Vol.18 (5), p.116-123

2013

Volltextzugriff (PDF)

Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance)

Journal of clinical oncology, 2023-02, Vol.41 (5), p.1023-1034

2023

Volltextzugriff (PDF)

P1088: COMPARISON OF BLEEDING‐RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS

HemaSphere, 2023-08, Vol.7, p.n/a

2023

Volltextzugriff (PDF)

Influence of the pH-value on the photocatalytic disinfection of bacteria with TiO2 – Explanation by DLVO and XDLVO theory

Water research (Oxford), 2013-03, Vol.47 (4), p.1503-1511

2013

Volltextzugriff (PDF)

Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis

Cancer medicine (Malden, MA), 2023-04, Vol.12 (7), p.8211-8217

2023

Volltextzugriff (PDF)

Notch1 Induces Defective Epithelial Surfactant Processing and Pulmonary Fibrosis

American journal of respiratory and critical care medicine, 2023-02, Vol.207 (3), p.283-299

2023

Volltextzugriff (PDF)

Regulation of Immunoproteasome Function in the Lung

Scientific reports, 2015-05, Vol.5 (1), p.10230-10230, Article 10230

2015

Volltextzugriff (PDF)

Quantitative proteomics of differentiated primary bronchial epithelial cells from chronic obstructive pulmonary disease and control identifies potential novel host factors post-influenza A virus infection

Frontiers in microbiology, 2023-01, Vol.13, p.957830-957830

2023

Volltextzugriff (PDF)

Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy

EJHaem, 2024-10, Vol.5 (5), p.929-939

2024

Volltextzugriff (PDF)

P1088: COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS

HemaSphere, 2023-08, Vol.7 (S3), p.e724362f

2023

Volltextzugriff (PDF)

CT-168 Comparison of Bleeding-Related Events in Patients Who Received Pirtobrutinib With and Without Antithrombotic Agents

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S520-S521

2023

Volltextzugriff (PDF)

POSTER: CT-168 Comparison of Bleeding-Related Events in Patients Who Received Pirtobrutinib With and Without Antithrombotic Agents

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S229-S229

2023

Volltextzugriff (PDF)

CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.7507-7507

2021

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(27)

Sprache

Englisch
(25)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Synthesis of Blue-Luminescent Seven-Membered Phosphorus Heterocycles

Calix[4]pyrrolato Stannate(II): A Tetraamido Tin(II) Dianion and Strong Metal‐Centered σ‐Donor

Calix4pyrrolato Stannate(II): A Tetraamido Tin(II) Dianion and Strong Metal-Centered σ-Donor

Calixpyrrolato Stannate(II): A Tetraamido Tin(II) Dianion and Strong Metal‐Centered σ‐Donor

Bis(alizarinato)silane: In Silico Design and Synthesis of a Powerful Chromogenic Lewis Acid as a Dual-Gated Fluoride Ion Probe

Calix[4]pyrroles as ligands: recent progress with a focus on the emerging p-block element chemistry

Conformational and Substitution Effects on the Donor and Reducing Strength of Tin(II) Porphyrinogens

Calix[4]pyrrolatostannat(II): Ein Tetraamidozinn(II)dianion als starker, metallzentrierter σ‐Donor

Calixpyrrolatostannat(II): Ein Tetraamidozinn(II)dianion als starker, metallzentrierter σ‐Donor

Concatenating Structural Constraint Effects at Tin for the Sequential Generation, Stabilization, and Transfer of Acyclic Aminocarbenes

Dynamic Coordination Behavior of a Structurally Constrained, Nucleophilic Sn(II) Towards Gold(I)

Erprobt, abgestimmt und als (S-)klasse befunden

Komfort und Sportlichkeit

Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance)

P1088: COMPARISON OF BLEEDING‐RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS

Influence of the pH-value on the photocatalytic disinfection of bacteria with TiO2 – Explanation by DLVO and XDLVO theory

Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis

Notch1 Induces Defective Epithelial Surfactant Processing and Pulmonary Fibrosis

Regulation of Immunoproteasome Function in the Lung

Quantitative proteomics of differentiated primary bronchial epithelial cells from chronic obstructive pulmonary disease and control identifies potential novel host factors post-influenza A virus infection

Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy

P1088: COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS

CT-168 Comparison of Bleeding-Related Events in Patients Who Received Pirtobrutinib With and Without Antithrombotic Agents

POSTER: CT-168 Comparison of Bleeding-Related Events in Patients Who Received Pirtobrutinib With and Without Antithrombotic Agents

CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL)

Suchergebnisse filtern